Diamyd Medical opens up for vaccine manufacturing in Umeå, Sweden

A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for the manufacture of recombinant GAD65, the active ingredient in the  therapeutic diabetes vaccine Diamyd[®].“The importance of being in control of your own manufacturing process has never been higher”, says Ulf Hannelius, CEO of Diamyd Medical. “Taking over the GAD manufacturing technology, a key process for the company, is a strategic, long-term decision to maximize shareholder value. It provides Diamyd Medical with direct control of the